The transport of molecules across biological membranes is a vital process for all aspects of cellular function and tissue homeostasis. Membrane transporters are the molecular gates that control this transport and serve as key points of cellular regulation, thus representing an attractive class of therapeutic targets. Mutations in these transporter systems have been increasingly implicated in a wide variety of metabolic diseases, including those that extend to bone. Bone resident cells express their own unique complement of transporters that are enriched on the cell surface as well as in membranes of intracellular organelles. This is best exemplified in osteoclasts whose specialised secretory organelles are equipped with structurally and functionally diverse membrane transport nanomachinery uniquely adapted to digest mineralised bone. Despite their obvious importance, our understanding of membrane transporter systems in bone homeostasis and disease remains in its infancy. In particular, compared to other mammalian systems, the nature and number of transporters that reside and operate on bone cell membranes remains poorly understood. This presentation will provide a brief overview of our current understanding of molecular transport systems in bone homeostasis and disease, with a focus on membrane transporters in osteoclasts. It will unveil new and unexpected transporters in osteoclasts and highlight their potential as therapeutic drug targets for the treatment of metabolic bone diseases.